Sternberg P, Aguilar H E, Drews C, Aaberg T M
Department of Ophthalmology, Emory University School of Medicine, Atlanta, Ga 30322.
Arch Ophthalmol. 1990 May;108(5):720-2. doi: 10.1001/archopht.1990.01070070106045.
Tissue plasminogen activator is a potent thrombolytic agent that recently has been used to treat postvitrectomy fibrin formation. However, a recent report noted anterior and posterior segment bleeding following intracameral tissue plasminogen activator injection. In this study, we performed lensectomy and vitrectomy in 20 rabbits. A retinal blood vessel was incised to stimulate intraocular hemorrhage; bleeding was controlled and vitreous hemorrhage aspirated. Postoperatively, one eye received a 0.1-mL injection of tissue plasminogen activator (25 micrograms); the other received balanced salt solution. The eyes receiving tissue plasminogen activator had a 28% incidence of increased anterior chamber blood and a 61% incidence of increased intravitreal blood. There was no evidence of postinjection bleeding in eyes receiving balanced salt solution. Most cases of bleeding occurred within 24 hours of tissue plasminogen activator injection. Administration of tissue plasminogen activator in the setting of segmented blood vessels may lead to intraocular hemorrhage.
组织型纤溶酶原激活剂是一种强效溶栓剂，最近已被用于治疗玻璃体切除术后的纤维蛋白形成。然而，最近有一份报告指出，前房内注射组织型纤溶酶原激活剂后出现了眼前段和眼后段出血。在本研究中，我们对20只兔子进行了晶状体切除术和玻璃体切除术。切开一条视网膜血管以刺激眼内出血；出血得到控制，并吸出玻璃体积血。术后，一只眼睛接受了0.1毫升组织型纤溶酶原激活剂（25微克）注射；另一只眼睛接受平衡盐溶液注射。接受组织型纤溶酶原激活剂的眼睛前房积血增加的发生率为28%，玻璃体内积血增加的发生率为61%。接受平衡盐溶液的眼睛没有注射后出血的迹象。大多数出血病例发生在组织型纤溶酶原激活剂注射后的24小时内。在血管分段的情况下给予组织型纤溶酶原激活剂可能会导致眼内出血。
